non responder to semaglutide Doctor, I'm not losing weight on the GLP1” 🛑👇🏻 When the scale refuses budge, it's incredibly easy to feel frustrated and assume the medication “just doesn't work for you.” But before 7 Reasons You Aren't Losing

Ozeki et al (2022) found that GLP1-RA semaglutide effectively reduces body adiposity while maintaining the skeletal muscle mass in obese Type 2 Diabetic patients. Xiang et al (2023) had similar findings, semaglutide can reduce the weight and fat of obese patients while effectively maintaining muscle mass and muscle strength. Chen et al (2023) conducted a 3-month intervention using dulaglutide in patients with Type 2 Diabetes, noting , dulaglutide intervention does not cause muscle and bone mass loss while inducing weight loss, and % change in body fat was independently associated with improved glucose control during dulaglutide therapy. With an increasing number of physicians and researchers relying on GLP-1 therapies for clinical care and research, it will continue to be crucial to track sensitive changes in body composition across different patient populations

PlexusDx's transparent flat-rate model means you know exactly what you'll pay each month, with no surprise increases as your dose adjusts

Regarding non-fatal myocardial infarction, there was no statistically significant difference (RR 1.18

exendin-4 (Fig